Patents by Inventor Yutaka Tagaya

Yutaka Tagaya has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240317848
    Abstract: The c-family cytokines, Interleukin-2 (IL-2), Interleukin-4 (IL-4), Interleukin-7 (IL-7), Interleukin-9 (IL-9), Interleukin-15 (IL-15), and Interleukin-21 (IL-21), are associated with important human diseases, such as alopecia and alopecia associated disorders. Compositions, methods, and kits to modulate signaling by at least one c-cytokine family member for inhibiting, ameliorating, reducing a severity of, treating, delaying the onset of, or preventing at least one alopecia related disorder are described.
    Type: Application
    Filed: May 21, 2024
    Publication date: September 26, 2024
    Inventors: Yutaka Tagaya, Nazli Azimi
  • Patent number: 12030936
    Abstract: The ?c-family cytokines, Interleukin-2 (IL-2), Interleukin-4 (IL-4), Interleukin-7 (IL-7), Interleukin-9 (IL-9), Interleukin-15 (IL-15), and Interleukin-21 (IL-21), are associated with important human diseases, such as alopecia and alopecia associated disorders. Compositions, methods, and kits to modulate signaling by at least one ?c-cytokine family member for inhibiting, ameliorating, reducing a severity of, treating, delaying the onset of, or preventing at least one alopecia related disorder are described.
    Type: Grant
    Filed: April 30, 2020
    Date of Patent: July 9, 2024
    Assignee: BIONIZ THERAPEUTICS, INC.
    Inventors: Yutaka Tagaya, Nazli Azimi
  • Publication number: 20240209025
    Abstract: The ?c-family cytokines, Interleukin-2 (IL-2), Interleukin-4 (IL-4), Interleukin-7 (IL-7), Interleukin-9 (IL-9), Interleukin-15 (IL-15), and Interleukin-21 (IL-21), are associated with important human diseases, such as leukemia, autoimmune diseases, collagen diseases, diabetes mellitus, skin diseases, degenerative neuronal diseases and graft-versus-host disease (GvHD). Thus, inhibitors of ?c-cytokine activity are valuable therapeutic and cosmetic agents as well as research tools. Peptide and/or peptide derivative antagonists based on the consensus ?c-subunit binding site to inhibit ?c-cytokine activity are described. Also described are peptide and/or peptide derivative antagonists exhibiting Simul-Block activity, and inhibiting the activity of multiple ?c-cytokine family members.
    Type: Application
    Filed: November 6, 2023
    Publication date: June 27, 2024
    Inventors: Yutaka Tagaya, Nazli Azimi
  • Publication number: 20240043475
    Abstract: Methods and compositions related to the selective, specific disruption of multiple ligand-receptor signaling interactions, such as ligand-receptor interactions implicated in disease, are disclosed. These interactions may involve multiple cytokines in a single receptor family or multiple ligand receptor interactions from at least two distinct ligand-receptor families. The compositions may comprise polypeptides having composite sequences that comprise sequence fragments of two or more ligand binding sites. The methods and compositions may involve sequence fragments of two or more ligand binding sites that are arranged to conserve the secondary structure of each of the ligands from which the sequence fragments were taken.
    Type: Application
    Filed: June 30, 2023
    Publication date: February 8, 2024
    Inventors: Yutaka Tagaya, Nazli Azimi
  • Patent number: 11834519
    Abstract: The ?c-family cytokines, Interleukin-2 (IL-2), Interleukin-4 (IL-4), Interleukin-7 (IL-7), Interleukin-9 (IL-9), Interleukin-15 (IL-15), and Interleukin-21 (IL-21), are associated with important human diseases, such as leukemia, autoimmune diseases, collagen diseases, diabetes mellitus, skin diseases, degenerative neuronal diseases and graft-versus-host disease (GvHD). Thus, inhibitors of ?c-cytokine activity are valuable therapeutic and cosmetic agents as well as research tools. Peptide and/or peptide derivative antagonists based on the consensus ?c-subunit binding site to inhibit ?c-cytokine activity are described. Also described are peptide and/or peptide derivative antagonists exhibiting Simul-Block activity, and inhibiting the activity of multiple ?c-cytokine family members.
    Type: Grant
    Filed: March 6, 2019
    Date of Patent: December 5, 2023
    Assignee: BIONIZ THERAPEUTICS, INC.
    Inventors: Yutaka Tagaya, Nazli Azimi
  • Publication number: 20230338473
    Abstract: The yc-family Interleukin-2 (IL-2), Interleukin-9 (IL-9), and Interleukin-15 (IL-15) cytokines are associated with important human diseases, such as cytokine-release syndrome and cytokine storm associated disorders. Compositions, methods, and kits to modulate signaling by at least one IL-2, IL-9, or IL-15 ?c-cytokine family members for inhibiting, ameliorating, reducing a severity of, treating, delaying the onset of, or preventing at least one cytokine storm related disorder are described.
    Type: Application
    Filed: June 22, 2021
    Publication date: October 26, 2023
    Inventors: Yutaka Tagaya, Nazli Azimi
  • Patent number: 11708392
    Abstract: Methods and compositions related to the selective, specific disruption of multiple ligand-receptor signaling interactions, such as ligand-receptor interactions implicated in disease, are disclosed. These interactions may involve multiple cytokines in a single receptor family or multiple ligand receptor interactions from at least two distinct ligand-receptor families. The compositions may comprise polypeptides having composite sequences that comprise sequence fragments of two or more ligand binding sites. The methods and compositions may involve sequence fragments of two or more ligand binding sites that are arranged to conserve the secondary structure of each of the ligands from which the sequence fragments were taken.
    Type: Grant
    Filed: September 4, 2020
    Date of Patent: July 25, 2023
    Assignee: BIONIZ, LLC
    Inventors: Yutaka Tagaya, Nazli Azimi
  • Publication number: 20230197187
    Abstract: Methods and compositions related to the selective, specific disruption of multiple ligand-receptor signaling interactions, such as ligand-receptor interactions implicated in disease, are disclosed. These interactions may involve multiple cytokines in a single receptor family or multiple ligand receptor interactions from at least two distinct ligand-receptor families. The compositions may comprise polypeptides having composite sequences that comprise sequence fragments of two or more ligand binding sites. The methods and compositions may involve sequence fragments of two or more ligand binding sites that are arranged to conserve the secondary structure of each of the ligands from which the sequence fragments were taken.
    Type: Application
    Filed: September 16, 2022
    Publication date: June 22, 2023
    Inventors: Nazli Azimi, Yutaka Tagaya
  • Patent number: 11462297
    Abstract: Methods and compositions related to the selective, specific disruption of multiple ligand-receptor signaling interactions, such as ligand-receptor interactions implicated in disease, are disclosed. These interactions may involve multiple cytokines in a single receptor family or multiple ligand receptor interactions from at least two distinct ligand-receptor families. The compositions may comprise polypeptides having composite sequences that comprise sequence fragments of two or more ligand binding sites. The methods and compositions may involve sequence fragments of two or more ligand binding sites that are arranged to conserve the secondary structure of each of the ligands from which the sequence fragments were taken.
    Type: Grant
    Filed: October 28, 2020
    Date of Patent: October 4, 2022
    Assignee: BIONIZ, LLC
    Inventors: Nazli Azimi, Yutaka Tagaya
  • Publication number: 20210082537
    Abstract: Methods and compositions related to the selective, specific disruption of multiple ligand-receptor signaling interactions, such as ligand-receptor interactions implicated in disease, are disclosed. These interactions may involve multiple cytokines in a single receptor family or multiple ligand receptor interactions from at least two distinct ligand-receptor families. The compositions may comprise polypeptides having composite sequences that comprise sequence fragments of two or more ligand binding sites. The methods and compositions may involve sequence fragments of two or more ligand binding sites that are arranged to conserve the secondary structure of each of the ligands from which the sequence fragments were taken.
    Type: Application
    Filed: October 28, 2020
    Publication date: March 18, 2021
    Inventors: Nazli Azimi, Yutaka Tagaya
  • Publication number: 20200399316
    Abstract: Methods and compositions related to the selective, specific disruption of multiple ligand-receptor signaling interactions, such as ligand-receptor interactions implicated in disease, are disclosed. These interactions may involve multiple cytokines in a single receptor family or multiple ligand receptor interactions from at least two distinct ligand-receptor families. The compositions may comprise polypeptides having composite sequences that comprise sequence fragments of two or more ligand binding sites. The methods and compositions may involve sequence fragments of two or more ligand binding sites that are arranged to conserve the secondary structure of each of the ligands from which the sequence fragments were taken.
    Type: Application
    Filed: September 4, 2020
    Publication date: December 24, 2020
    Inventors: Yutaka Tagaya, Nazli Azimi
  • Patent number: 10854312
    Abstract: Methods and compositions related to the selective, specific disruption of multiple ligand-receptor signaling interactions, such as ligand-receptor interactions implicated in disease, are disclosed. These interactions may involve multiple cytokines in a single receptor family or multiple ligand receptor interactions from at least two distinct ligand-receptor families. The compositions may comprise polypeptides having composite sequences that comprise sequence fragments of two or more ligand binding sites. The methods and compositions may involve sequence fragments of two or more ligand binding sites that are arranged to conserve the secondary structure of each of the ligands from which the sequence fragments were taken.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: December 1, 2020
    Assignee: BIONIZ, LLC
    Inventors: Nazli Azimi, Yutaka Tagaya
  • Publication number: 20200347128
    Abstract: The ?c-family cytokines, Interleukin-2 (IL-2), Interleukin-4 (IL-4), Interleukin-7 (IL-7), Interleukin-9 (IL-9), Interleukin-15 (IL-15), and Interleukin-21 (IL-21), are associated with important human diseases, such as alopecia and alopecia associated disorders. Compositions, methods, and kits to modulate signaling by at least one ?c-cytokine family member for inhibiting, ameliorating, reducing a severity of, treating, delaying the onset of, or preventing at least one alopecia related disorder are described.
    Type: Application
    Filed: April 30, 2020
    Publication date: November 5, 2020
    Inventors: Yutaka Tagaya, Nazli Azimi
  • Patent number: 10808009
    Abstract: Methods and compositions related to the selective, specific disruption of multiple ligand-receptor signaling interactions, such as ligand-receptor interactions implicated in disease, are disclosed. These interactions may involve multiple cytokines in a single receptor family or multiple ligand receptor interactions from at least two distinct ligand-receptor families. The compositions may comprise polypeptides having composite sequences that comprise sequence fragments of two or more ligand binding sites. The methods and compositions may involve sequence fragments of two or more ligand binding sites that are arranged to conserve the secondary structure of each of the ligands from which the sequence fragments were taken.
    Type: Grant
    Filed: April 19, 2018
    Date of Patent: October 20, 2020
    Assignee: BIONIZ, LLC
    Inventors: Yutaka Tagaya, Nazli Azimi
  • Publication number: 20190194255
    Abstract: The ?c-family cytokines, Interleukin-2 (IL-2), Interleukin-4 (IL-4), Interleukin-7 (IL-7), Interleukin-9 (IL-9), Interleukin-15 (IL-15), and Interleukin-21 (IL-21), are associated with important human diseases, such as leukemia, autoimmune diseases, collagen diseases, diabetes mellitus, skin diseases, degenerative neuronal diseases and graft-versus-host disease (GvHD). Thus, inhibitors of ?c-cytokine activity are valuable therapeutic and cosmetic agents as well as research tools. Peptide and/or peptide derivative antagonists based on the consensus ?c-subunit binding site to inhibit ?c-cytokine activity are described. Also described are peptide and/or peptide derivative antagonists exhibiting Simul-Block activity, and inhibiting the activity of multiple ?c-cytokine family members.
    Type: Application
    Filed: March 6, 2019
    Publication date: June 27, 2019
    Inventors: Yutaka Tagaya, Nazli Azimi
  • Patent number: 10227382
    Abstract: The ?c-family cytokines, Interleukin-2 (IL-2), Interleukin-4 (IL-4), Interleukin-7 (IL-7), Interleukin-9 (IL-9), Interleukin-15 (IL-15), and Interleukin-21 (IL-21), are associated with important human diseases, such as leukemia, autoimmune diseases, collagen diseases, diabetes mellitus, skin diseases, degenerative neuronal diseases and graft-versus-host disease (GvHD). Thus, inhibitors of ?c-cytokine activity are valuable therapeutic and cosmetic agents as well as research tools. Peptide and/or peptide derivative antagonists based on the consensus ?c-subunit binding site to inhibit ?c-cytokine activity are described. Also described are peptide and/or peptide derivative antagonists exhibiting Simul-Block activity, and inhibiting the activity of multiple ?c-cytokine family members.
    Type: Grant
    Filed: March 30, 2017
    Date of Patent: March 12, 2019
    Assignee: BIONIZ, LLC
    Inventors: Yutaka Tagaya, Nazli Azimi
  • Publication number: 20180349550
    Abstract: Methods and compositions related to the selective, specific disruption of multiple ligand-receptor signaling interactions, such as ligand-receptor interactions implicated in disease, are disclosed. These interactions may involve multiple cytokines in a single receptor family or multiple ligand receptor interactions from at least two distinct ligand-receptor families. The compositions may comprise polypeptides having composite sequences that comprise sequence fragments of two or more ligand binding sites. The methods and compositions may involve sequence fragments of two or more ligand binding sites that are arranged to conserve the secondary structure of each of the ligands from which the sequence fragments were taken.
    Type: Application
    Filed: April 27, 2018
    Publication date: December 6, 2018
    Inventors: Nazli Azimi, Yutaka Tagaya
  • Publication number: 20180237475
    Abstract: Methods and compositions related to the selective, specific disruption of multiple ligand-receptor signaling interactions, such as ligand-receptor interactions implicated in disease, are disclosed. These interactions may involve multiple cytokines in a single receptor family or multiple ligand receptor interactions from at least two distinct ligand-receptor families. The compositions may comprise polypeptides having composite sequences that comprise sequence fragments of two or more ligand binding sites. The methods and compositions may involve sequence fragments of two or more ligand binding sites that are arranged to conserve the secondary structure of each of the ligands from which the sequence fragments were taken.
    Type: Application
    Filed: April 19, 2018
    Publication date: August 23, 2018
    Inventors: Yutaka Tagaya, Nazli Azimi
  • Patent number: 9959384
    Abstract: Methods and compositions related to the selective, specific disruption of multiple ligand-receptor signaling interactions, such as ligand-receptor interactions implicated in disease, are disclosed. These interactions may involve multiple cytokines in a single receptor family or multiple ligand receptor interactions from at least two distinct ligand-receptor families. The compositions may comprise polypeptides having composite sequences that comprise sequence fragments of two or more ligand binding sites. The methods and compositions may involve sequence fragments of two or more ligand binding sites that are arranged to conserve the secondary structure of each of the ligands from which the sequence fragments were taken.
    Type: Grant
    Filed: December 10, 2014
    Date of Patent: May 1, 2018
    Assignee: BIONIZ, LLC
    Inventors: Nazli Azimi, Yutaka Tagaya
  • Patent number: 9951105
    Abstract: Methods and compositions related to the selective, specific disruption of multiple ligand-receptor signaling interactions, such as ligand-receptor interactions implicated in disease, are disclosed. These interactions may involve multiple cytokines in a single receptor family or multiple ligand receptor interactions from at least two distinct ligand-receptor families. The compositions may comprise polypeptides having composite sequences that comprise sequence fragments of two or more ligand binding sites. The methods and compositions may involve sequence fragments of two or more ligand binding sites that are arranged to conserve the secondary structure of each of the ligands from which the sequence fragments were taken.
    Type: Grant
    Filed: June 10, 2016
    Date of Patent: April 24, 2018
    Assignee: BIONIZ, LLC
    Inventors: Yutaka Tagaya, Nazli Azimi